| Autor: |
Pruis MA; Department of Respiratory Medicine, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Paats MS; Department of Respiratory Medicine, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Geurts WRR; Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Dubbink HJ; Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Dingemans AC; Department of Respiratory Medicine, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. |
| Abstrakt: |
Competing Interests: H. J. DubbinkConsulting or Advisory Role: Janssen, AstraZeneca, AbbVie, Janssen-Cilag B.V, Bayer, LillyResearch Funding: AstraZeneca, AstraZeneca/Merck Anne-Marie DingemansConsulting or Advisory Role: Roche/Genentech, Boehringer Ingelheim, Amgen, Pharmamar, Bayer, SanofiSpeakers' Bureau: JanssenResearch Funding: AbbVie, AmgenNo other potential conflicts of interest were reported. |
